To further demonstrate whether methionine regulates AD progression by modulating GSK-3β, the results of our experiments revealed that methionine deficiency or excess no longer altered A-β and p-Tau levels when we treated SH-SY5Y cells with the GSK-3β inhibitor, the above results proved our speculation (Figure 4D). This evidence concerns the gene MAPT and Alzheimer disease.